RVL Pharmaceuticals (RVLPQ) Stock Statistics & Valuation Metrics

RVL Pharmaceuticals has a market cap or net worth of $111.00. The enterprise value is $113.52M.

RVL Pharmaceuticals has 111,406,044 shares outstanding. The number of shares has decreased by -2.65% in one year.

RVL Pharmaceuticals’s return on equity (ROE) is -1.01 and return on invested capital (ROIC) is -53.28%.

The current PE Ratio of RVL Pharmaceuticals is -1.95. RVL Pharmaceuticals’s PEG ratio is 0.05.

In the last 12 months, RVL Pharmaceuticals had revenue of 49.72M and earned -51.69M in profits. Earnings per share was -0.58.

In the last 12 months, operating cash flow was -44.41M and capital expenditures -3.08M, giving a free cash flow of -47.48M billion.

RVL Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

RVL Pharmaceuticals upcoming earnings date is Aug 12, 2024, TBA Not Confirmed.

RVL Pharmaceuticals as a current ratio of 2.89, with Debt / Equity ratio of 112.52%

In the past 12 months, RVL Pharmaceuticals has paid -20.00K in taxes.

RVL Pharmaceuticals EV to EBITDA ratio is -2.35, with an EV/FCF ratio of -2.94.

RVL Pharmaceuticals has $19.16M in cash and marketable securities with $58.15M in debt, giving a net cash position of $38.99M billion.

Gross margin is 80.98%, with operating margin of -118.64%, and net profit margin of -103.96%.

The average price target for RVL Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―